<DOC>
	<DOC>NCT01541943</DOC>
	<brief_summary>The purpose of this study is to evaluate efficacy and safety of HL-040XC in patients with essential hypertension and hyperlipidemia</brief_summary>
	<brief_title>Efficacy and Safety of HL-040XC in Essential Hypertension and Hyperlipidemia</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Losartan</mesh_term>
	<criteria>Aged between 18 and 80 years History of essential hypertension and hyperlipidemia Able to sign informed consent At screening, SBP ≥ 180mmHg or DBP ≥ 110mmHg or LDLC &gt; 250mg/dL or TG ≥ 400mg/dL Has a history of hypersensitivity to Angiotensin Ⅱ receptor blocker or HMGCoA reductase inhibitor or component of this drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Atorvastatin</keyword>
	<keyword>Losartan</keyword>
	<keyword>Essential Hypertension</keyword>
	<keyword>Hyperlipidemia</keyword>
</DOC>